- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2443EUR$2,789USD£2,120GBP
- Report
- March 2025
- 145 Pages
Global
From €4248EUR$4,850USD£3,687GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €2049EUR$2,340USD£1,779GBP
€3153EUR$3,600USD£2,737GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4160EUR$4,750USD£3,611GBP
- Report
- January 2026
- 70 Pages
Indonesia
From €4160EUR$4,750USD£3,611GBP
Glimepiride is a drug used to treat type 2 diabetes, a condition in which the body does not produce or use insulin properly. It belongs to a class of drugs known as sulfonylureas, which work by stimulating the pancreas to produce more insulin. Glimepiride is used in combination with diet and exercise to help control blood sugar levels. It is also used to reduce the risk of cardiovascular disease in people with type 2 diabetes.
Glimepiride is a widely used drug in the endocrine and metabolic disorders drugs market. It is used to treat type 2 diabetes, a condition that affects millions of people worldwide. It is a cost-effective and safe treatment option for many patients. It is also used to reduce the risk of cardiovascular disease in people with type 2 diabetes.
Some companies in the glimepiride market include Sanofi, Novo Nordisk, Merck, and Eli Lilly. Show Less Read more
